Platelet-rich plasma to prevent uterine scar problems after cesarean
Platelet Rich Plasma for the Treatment of Uterine Scar
This test will see if applying your own platelet-rich plasma to the uterine incision at an elective term cesarean can reduce scar-related bleeding, pain, and menstrual problems.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 52 Years |
| Sex | Female |
| Sponsor | The University of Texas Health Science Center, Houston Academic / other |
| Locations | 1 site (Ramat Gan, Center) |
| Trial ID | NCT05224726 on ClinicalTrials.gov |
What this trial studies
Participants undergoing elective cesarean delivery at term will have a sample of their blood processed into platelet-rich plasma (PRP) during the operative visit. The PRP preparation or a placebo will be applied to the uterine scar site at the time of closure. Outcomes will focus on healing-related measures and clinical complaints such as post-cesarean bleeding, pelvic pain, and menstrual irregularities linked to uterine scar defects. The approach uses autologous material to concentrate growth factors that may enhance local wound repair.
Who should consider this trial
Good fit: Women with a term pregnancy (≥37 weeks) scheduled for an elective cesarean who do not have exclusion conditions such as very low platelets or non-cesarean uterine scars would be ideal candidates.
Not a fit: Patients with thrombocytopenia, connective tissue disease, prior non-cesarean uterine surgery, or congenital uterine malformations are excluded and are unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, this could reduce the frequency or severity of uterine scar defects and the bleeding, pain, or menstrual issues that follow some cesarean deliveries.
How similar studies have performed: PRP has shown promising results for wound healing and endometrial/follicular support in other surgical and reproductive settings, but its use specifically to prevent cesarean-related uterine scar defects is relatively novel and not yet widely proven.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Women undergoing elective cesarean delivery * Term pregnancy (≥37 weeks of gestation) Exclusion criteria: * Thrombocytopenia (CBC Platelet count \<70,000) * Connective tissue disease * Uterine scars other than cesarean (s/p myomectomy, s/p cornual resection) * Malformed uterus (unicornuate, bicornuate, didelphic)
Where this trial is running
Ramat Gan, Center
- Sheba Medical Center — Ramat Gan, Center, Israel (Recruiting)
Study contacts
- Study coordinator: Aya A Mohr-Sasson, M.D
- Email: mohraya@gmail.com
- Phone: 3462704682
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.